Amifostine trihydrate ( DrugBank: Amifostine )


1 disease
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis1

28. Systemic amyloidosis


Clinical trials : 261 Drugs : 276 - (DrugBank : 81) / Drug target genes : 68 - Drug target pathways : 178
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00052884
(ClinicalTrials.gov)
October 200324/1/2003Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell TransplantationA Phase I Study of Amifostine Followed by High-Dose Escalation of Melphalan With Stem Cell Reconstitution for Patients With Primary Systemic AmyloidosisDrug/Agent Toxicity by Tissue/Organ;Multiple Myeloma and Plasma Cell NeoplasmBiological: filgrastim;Drug: amifostine trihydrate;Drug: melphalan;Procedure: bone marrow ablation with stem cell support;Procedure: peripheral blood stem cell transplantationEastern Cooperative Oncology GroupNational Cancer Institute (NCI)Terminated18 Years70 YearsBoth8Phase 1United States